loading
Überblick Nachrichten Preisverlauf Forum Prognose
Schlusskurs vom Vortag:
$1.81
Offen:
$1.77
24-Stunden-Volumen:
43,147
Relative Volume:
0.16
Marktkapitalisierung:
$66.35M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-8.82M
KGV:
-6.0667
EPS:
-0.3
Netto-Cashflow:
$-18.01M
1W Leistung:
-15.41%
1M Leistung:
-21.00%
6M Leistung:
+88.78%
1J Leistung:
+41.21%
1-Tages-Spanne:
Value
$1.7401
$1.88
1-Wochen-Bereich:
Value
$1.67
$2.16
52-Wochen-Spanne:
Value
$0.7301
$3.15

Estrella Immunopharma Inc Stock (ESLA) Company Profile

Name
Firmenname
Estrella Immunopharma Inc
Name
Sektor
Healthcare (1132)
Name
Branche
Biotechnology (631)
Name
Telefon
(510) 318-9098
Name
Adresse
5858 HORTON STREET, SUITE 370, EMERYVILLE
Name
Mitarbeiter
0
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
ESLA's Discussions on Twitter

Vergleichen Sie ESLA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ESLA
Estrella Immunopharma Inc
 1.7569 68.36M 0 -8.82M -18.01M -0.30
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
 456.90 115.62B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
 745.00 79.10B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ARGX
Argen X Se Adr
 849.08 52.39B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
 397.26 51.72B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
INSM
Insmed Inc
 200.98 42.00B 447.02M -1.18B -906.14M -6.1812

Estrella Immunopharma Inc Aktie (ESLA) Neueste Nachrichten

pulisher
03:57 AM

Estrella Immunopharma (NASDAQ:ESLA) & Foghorn Therapeutics (NASDAQ:FHTX) Head-To-Head Contrast - Defense World

03:57 AM
pulisher
Dec 13, 2025

Estrella Immunopharma advances STARLIGHT-1 trial after DSMB review - MSN

Dec 13, 2025
pulisher
Dec 12, 2025

Estrella Immunopharma secures $3.35M in financing to advance clinical triall; shares up - MSN

Dec 12, 2025
pulisher
Dec 07, 2025

Estrella Immunopharma shares gain as CD19 cancer therapy progresses into phase II - MSN

Dec 07, 2025
pulisher
Dec 06, 2025

Estrella Immunopharma (ESLA) Stock Analysis Report | Financials & Insights - Benzinga

Dec 06, 2025
pulisher
Dec 05, 2025

Estrella’s EB103 advances to Phase II after positive safety data By Investing.com - Investing.com Nigeria

Dec 05, 2025
pulisher
Dec 04, 2025

Estrella Immunopharma Advances STARLIGHT-1 Trial to Phase II - TradingView — Track All Markets

Dec 04, 2025
pulisher
Dec 04, 2025

Estrella Immunopharma stock rises as cancer therapy advances to Phase II - Investing.com Canada

Dec 04, 2025
pulisher
Dec 04, 2025

Estrella’s EB103 advances to Phase II after positive safety data - Investing.com

Dec 04, 2025
pulisher
Dec 04, 2025

Estrella advances Starlight-1 trial into phase II following positive DSMB recommendation - marketscreener.com

Dec 04, 2025
pulisher
Dec 04, 2025

Estrella (NASDAQ: ESLA) passes DSMB; EB103 high-dose cohort reports 100% CR - Stock Titan

Dec 04, 2025
pulisher
Dec 04, 2025

Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation - Business Wire

Dec 04, 2025
pulisher
Dec 04, 2025

Is Estrella Immunopharma Inc. stock a defensive play in 2025Portfolio Gains Summary & Daily Growth Stock Investment Tips - Newser

Dec 04, 2025
pulisher
Nov 30, 2025

Here's Why We're Not Too Worried About Estrella Immunopharma's (NASDAQ:ESLA) Cash Burn Situation - Sahm

Nov 30, 2025
pulisher
Nov 22, 2025

Estrella Immunopharma (NASDAQ:ESLA) Raised to “Hold” at Wall Street Zen - Defense World

Nov 22, 2025
pulisher
Nov 22, 2025

Estrella Immunopharma (NASDAQ:ESLA) Raised to "Hold" at Wall Street Zen - MarketBeat

Nov 22, 2025
pulisher
Nov 20, 2025

How Estrella Immunopharma Inc. stock benefits from global expansionInsider Buying & Free Technical Pattern Based Buy Signals - newser.com

Nov 20, 2025
pulisher
Nov 20, 2025

Published on: 2025-11-19 23:49:15 - newser.com

Nov 20, 2025
pulisher
Nov 19, 2025

Is Estrella Immunopharma Inc. stock oversold or undervaluedStock Surge & Free High Accuracy Swing Entry Alerts - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

What data driven models say about Estrella Immunopharma Inc.’s futureJuly 2025 Highlights & Capital Protection Trade Alerts - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Is now a turning point for Estrella Immunopharma Inc.July 2025 Chart Watch & Advanced Technical Analysis Signals - newser.com

Nov 19, 2025
pulisher
Nov 16, 2025

Is Estrella Immunopharma Inc. building a consolidation baseMarket Trend Review & Precise Buy Zone Tips - newser.com

Nov 16, 2025
pulisher
Nov 16, 2025

Will Estrella Immunopharma Inc. stock gain from government policies2025 Key Lessons & AI Driven Stock Price Forecasts - newser.com

Nov 16, 2025
pulisher
Nov 15, 2025

Published on: 2025-11-15 19:23:21 - newser.com

Nov 15, 2025
pulisher
Nov 15, 2025

Is Estrella Immunopharma Inc. reversing from oversold territoryEntry Point & Step-by-Step Swing Trade Plans - newser.com

Nov 15, 2025
pulisher
Nov 15, 2025

How to integrate Estrella Immunopharma Inc. into portfolio analysis tools - newser.com

Nov 15, 2025
pulisher
Nov 14, 2025

Published on: 2025-11-14 10:46:07 - newser.com

Nov 14, 2025
pulisher
Nov 14, 2025

10-Q: Quarterly report - 富途牛牛

Nov 14, 2025

Finanzdaten der Estrella Immunopharma Inc-Aktie (ESLA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Ähnlich wie ESLA

biotechnology RPRX
$38.53
price up icon 0.42%
biotechnology INCY
$98.38
price down icon 0.32%
biotechnology GMAB
$31.57
price up icon 0.83%
biotechnology BNTX
$93.57
price down icon 0.31%
biotechnology ONC
$300.09
price down icon 5.87%
biotechnology INSM
$196.92
price down icon 1.22%
In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters
Kapitalisierung:     |  Volumen (24h):